NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
In 1961 the use of levodopa was introduced into the treatment of Parkinson's disease (PD). Since bradykinesia seems to reflect the death of dopaminergic nigrostriatal neurons, this observation makes sense. To date, levodopa in combination with a decarboxylase inhibitor is the safest and most efficacious oral treatment in PD. Over the last decades, motor fluctuations, the most important roblem associated with levodopa and due to its short plasma half life have been improved by the addition of MAOB-, COMT-inhibitors and dopamine agonists. Long-acting levodopa formulations are available to keep wearing-off low and to allow the use of 2-3 levodopa tablets per day. Rescue medication, such as oral soluble levodopa/carbidopa or sublingual apomorphine is available as is subcutaneously applied levodopa/carbidopa, a new tool in advice-guided therapy to come near to physiological continuous dopamine receptor stimulation and in this way allow persistent motor control. Most subtances used in PD treatment function via the dopaminergic system. One exception is amantadine, which shows anti-glutamatergic function. At present, modern treatment of PD is a dopamine replacement therapy and probably this will stay that way for a long time to come.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.